



Research Article

Promising Antibacterial Effect of Copper Oxide Nanoparticles against Several Multidrug Resistant Uropathogens

Hadi Sedigh Ebrahim-Saraie^{1,2}, Hamid Heidari^{1,2}, Vahid Rezaei¹, Seyed Mohammad Javad Mortazavi³, Mohammad Motamedifar^{1,2,4*}

¹Nanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

²Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

³Department of Medical Physics and Medical Engineering, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

⁴Shiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.

Article Info

Article History:

Received: 4 March 2018

Revised: 29 April 2018

Accepted: 2 May 2018

ePublished: 23 September 2018

Keywords:

-Antibacterial effect

-Nanoparticles

-Copper oxide

-Uropathogenic bacteria

ABSTRACT

Background: Recently, nanotechnology has been demonstrated to be a promising application to overcome the problem of antibiotic resistance. In the present study, we aimed to determine the antibacterial activity of copper oxide nanoparticles (CuO NPs) on several multiple-drug resistant (MDR) uropathogenic strains.

Methods: This *in vitro* case-control study was performed on 4 uropathogenic bacteria including *Staphylococcus aureus*, *Enterococcus faecalis*, *Escherichia coli* and *Pseudomonas aeruginosa*. The antibacterial property was evaluated by well diffusion method at different concentrations of CuO NPs.

Results: Overall, NPs concentration of 10, 25 and 50 µg/mL showed the remarkable antibacterial activity. A lower effect was seen against *S. aureus* strains. CuO NPs exhibited maximum bacterial growth inhibition against *E. faecalis* strains. In most of the cases, the zone of inhibition in 50 µg/mL concentration was closest to control positive antibiotics.

Conclusion: In summary, CuO NPs as an alternative to conventional antibiotics that are currently used showed dose-dependent on antibacterial activity against different uropathogens, specificity towards pathogenic Gram-positive bacteria. This promising antibacterial activity of CuO NPs suggesting the development of NPs coatings on the different surface of biomedical materials for applications in different antimicrobial control systems.

Introduction

Nosocomial infections (NIs) are a common consequence of hospitalization which is associated with high morbidity and mortality.¹ Bacterial infections are one of the main causes of NIs and the frequently isolated pathogens are *Escherichia coli*, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, and enterococci.² Antimicrobial resistance increase is the major concern in hospital environments.³ NIs are associated with longest hospitalization time and subsequently risk of emergence of resistant bacteria against available antibiotic agents.¹

The profound effect of antimicrobial agents on the course of NIs is undeniable; however, with their broad use and abuse, the emergence of drug-resistant bacteria has become a major problem.⁴ Previously, several studies reported the emergence of multiple-drug resistant (MDR) pathogens including vancomycin-resistant enterococci (VRE), methicillin-resistant *S. aureus* (MRSA) and extended spectrum β-lactamase (ESBL) producing Gram-negative bacteria among Iranian patients.⁵⁻⁷

Dealing with antibiotic-resistant bacteria is costly and

requires more time and may be associated with side effects and sometimes therapeutic failure.^{3,8} Therefore, researchers are looking for an alternative and novel antimicrobial agents.⁹ In this case, nanotechnology has been demonstrated to be a promising application to overcome the problem of antibiotic resistance.¹⁰ Recent studies showed that nanoparticles (NPs) can have a broad spectrum of antimicrobial activity against different clinically isolated bacteria.¹⁰ Generally, the antimicrobial activity of the NPs may be varied based on their composition and type of pathogens.^{10,11} Moreover, antimicrobial NPs exhibit numerous distinct benefits in reducing acute toxicity, overcoming the existing antibiotic resistance mechanisms, targeted drug delivery, combinatorial antibiotic delivery, and vaccine development when compared to conventional antibiotics.¹²

Compared to published reports on antimicrobial properties of metal NPs, very limited information is available on the antibacterial activity of NPs on clinically obtained isolates. In the present study, we aimed to

*Corresponding Author: Mohammad Motamedifar, E-mail: motamedm@sums.ac.ir

©2018 The Authors. This is an open access article and applies the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.

determine antibacterial activity of CuO NPs on several MDR uropathogenic strains obtained from Iranian patients.

Materials and Methods

Study design and bacterial strains

This *in vitro* case-control study was performed in the Department of Bacteriology and Virology, Shiraz University of Medical Sciences, Shiraz, Iran in 2016. The bacterial strains used in the study were *S. aureus* ATCC 25923, *Enterococcus faecalis* ATCC 29212, *E. coli* ATCC 25922, *P. aeruginosa* ATCC 27853, and 10 clinical isolates from each mentioned bacteria. Clinical isolates were 40 nonduplicate bacteria obtained from urine specimens which were collected within 2012-2016 as parts of previous published and unpublished works from Nemazee hospital in Shiraz, Iran.^{13,14} All clinical isolates were MDR according to previous published criteria.¹⁵

Characterization of nanoparticles

The used Copper oxide (CuO) NPs purchased from Neutrino Corporation, Iran. The proper amount of the nano CuO was added to distilled water and dispersed by sonication. After that, tween 20 was added to the solution and the stock solution was sonicated for 10 min. Four different concentrations (5, 10, 25, and 50 µg/mL) of nano CuO for antibacterial assay were provided.

Antimicrobial susceptibility testing

Antibacterial property of the CuO NPs against Gram-positive and negative bacteria was evaluated by well diffusion method on Muller-Hinton agar (MHA; Merck, Germany) described by Nanda et al.¹⁶ Briefly, the bacterial suspension was prepared by making a saline suspension of bacterial colonies. The suspension was adjusted to the tube of 0.5 McFarland turbidity standard, which equals to 1.5×10^8 colony forming units (CFU)/ml.

The suspension was inoculated on the surface of MHA by using a sterile swab. Then, 5 mm wells were punched into the nutrient agar plates for testing NPs antimicrobial activity. Finally, 30 µL of different CuO NPs concentration was added into the wells. All plates were incubated on a rotary shaker at 160 rpm at 37 °C for 24 h and the clear zone of the growth inhibition was measured. Moreover, antibiotic susceptibility was determined toward teicoplanin (30 µg), imipenem (10 µg), polymyxin B (300 units) and fosfomycin (200 µg) antibiotic discs (MAST, UK) as the positive control. All tests were done in triplicate.

Statistical analysis

Analysis was performed by using SPSS™ software, version 21.0 (IBM Corp., USA). The results are presented as descriptive statistics in terms of relative frequency. Values are expressed as the mean ± standard deviation (continuous variables) or percentages of the group (categorical variables). Chi-square or Fisher's exact tests was used to estimate the statistical association. Statistical significance was regarded as P values less than 0.05.

Results

The size and purity of the used spherical CuO NPs in the present study were < 50 nm and 99%, respectively (Figure 1). Antibacterial susceptibility testing revealed CuO NPs inhibited the growth of uropathogenic bacteria (Figure 2). The full results of antibacterial activity of CuO NPs against Gram-positive and negative uropathogenic bacteria are presented in Tables 1 and 2, respectively. Overall, NPs concentration of 10, 25 and 50 µg/mL showed remarkable antibacterial activity with a zone of inhibition more than 10 mm. A lower effect was seen against *S. aureus* strains, since none of the isolates was susceptible to 10 µg/mL concentration. Moreover, the most sensitive isolates toward CuO NPs were *E. faecalis* strains.




Figure 1. Atomic force microscopy (AFM) image of copper oxide (CuO) nanoparticles.

CuO NPs exhibited maximum bacterial growth inhibition against *E. faecalis* uropathogenic isolates and *E. faecalis* standard strains with zone of inhibition 22.9 ± 1.7 mm and 22 ± 1 mm, respectively. The majority of clinical isolates showed higher sensitivity to CuO NPs compared to standard strains. In most of the cases, the zone of inhibition in 50 $\mu\text{g/mL}$ concentration was closest to positive control antibiotics.

Discussion

Urinary tract infections (UTIs) are the most common urological disease approximately known to occur in all age groups.¹⁷ *E. coli*, *S. aureus*, *E. faecalis* and *P. aeruginosa* are prevalent uropathogenic bacteria which are well-known for biofilm producing ability.^{17,18} Catheter-associated UTI accounts for a high rate of nosocomial infections mostly associated with biofilm producing bacteria.¹⁸




Figure 2. Antibacterial activity of copper oxide nanoparticles against uropathogens by well diffusion method; A, *P. aeruginosa*; B, *E. coli*; C, *S. aureus*, D, *E. faecalis*.

Table 1. The mean diameter (mm) zone of inhibition of Gram-positive strains against nanoparticles.

Concentration	ATCC 25923 (mean \pm SD)	Clinical <i>S. aureus</i> (mean \pm SD)	P value	ATCC 29212 (mean \pm SD)	Clinical <i>E. faecalis</i> (mean \pm SD)	P value
CuO 5 $\mu\text{g/mL}$	0	0	ND ^a	0	0	ND
CuO 10 $\mu\text{g/mL}$	0	0	ND	10 \pm 1	9.4 \pm 0.8	0.3
CuO 25 $\mu\text{g/mL}$	12.7 \pm 0.6	14.4 \pm 1.3	0.06	13.7 \pm 1.1	14 \pm 1.6	0.77
CuO 50 $\mu\text{g/mL}$	15.7 \pm 0.6	17.4 \pm 1.2	0.04	22 \pm 1	22.9 \pm 1.7	0.41
Teicoplanin (30 μg)	18.7 \pm 0.6	14.7 \pm 0.8	<0.001	-	-	-
Fosfomycin (200 μg)	-	-	-	26 \pm 1	27.7 \pm 3.4	0.42

^aNot determined

Table 2. The mean diameter (mm) zone of inhibition of Gram-negative strains against nanoparticles.

Concentration	ATCC 25922 (mean \pm SD)	Clinical <i>E. coli</i> (mean \pm SD)	P value	ATCC 27853 (mean \pm SD)	Clinical <i>P. aeruginosa</i> (mean \pm SD)	P value
CuO 5 $\mu\text{g/mL}$	0	0	ND ^a	0	0	ND
CuO 10 $\mu\text{g/mL}$	9.3 \pm 0.6	9.1 \pm 0.6	0.62	10 \pm 1	10.6 \pm 0.8	0.31
CuO 25 $\mu\text{g/mL}$	13 \pm 1	14 \pm 1.2	0.22	14 \pm 1	16.1 \pm 1.1	0.01
CuO 50 $\mu\text{g/mL}$	15 \pm 1	16.7 \pm 1.4	0.08	18.3 \pm 0.6	19.4 \pm 1.2	0.16
Imipenem (10 μg)	30.6 \pm 0.6	30.8 \pm 1.1	0.77	-	-	-
Polymyxin B (300 units)	-	-	-	13 \pm 1	13.5 \pm 1.2	0.52

^aNot determined

Resistant nature of biofilm community to antibiotics and host defenses eradication of causative agents are challenging to physicians.¹⁸ Coated NPs catheters can be a promising solution and may be useful in reducing the biofilm formation risk in patients with indwelling catheters.¹⁸ Since, it has been suggested that NPs due to their small size may directly penetrate through the exopolysaccharide structures of biofilm and deliver antimicrobial function.¹²

In the present study, CuO NPs showed promising antibacterial effects on several Gram-positive and negative strains. Previously, in accordance to our findings several studies documented antimicrobial properties of copper NPs on different bacterial strains including *E. coli*, *S. aureus* and *P. aeruginosa*.¹⁹⁻²¹ NPs can induce their antibacterial effects through different mechanisms including rupture via attachment to the negatively charged bacterial cell wall, reacting to sulfhydryl groups and causing respiration blockage and cell death, proton motive force destruction or binding with DNA molecules and leading to helical disruption.^{11,22}

In our results, NPs showed their antibacterial effects in a dose-dependent manner, since zone of inhibition increased with elevating concentration. In agreement with our finding two reports showed dose dependence antibacterial activity of CuO and silver (Ag) NPs on different Gram-positive and -negative pathogens.^{20,23} The effective concentrations of NPs in the present study ranged from 10 to 50 µg/mL. Our results was comparable with previous findings in experiments with different metal oxide NPs;¹¹ however, biological activity of NPs may vary depending on the type of NPs, size, synthesis method, and the tested organism.^{11,20}

It was previously documented that the Ag, CuO and ZnO NPs antibacterial effect is more significant against Gram-positive strains than Gram-negative strains.^{24,25} As seen in our results, CuO NPs exhibited maximum growth suppression against Gram-positive strains (*E. faecalis* strains). The structural dissimilarities of the external cell wall of Gram-positive and Gram-negative bacteria may be an explanation for such observations.²⁴

Several authors showed antimicrobial effects of smallest Cu NPs ranging from 8 nm to 40 nm, which was comparable with results of our tested CuO NPs with a mean size less than 50 nm.²⁶⁻²⁸ Based on previous reports, NPs with different mean size can exhibit different antibacterial activity.²⁹ It has been proposed that metal NPs in suspension may release metal ions into the medium.²⁹ In this regard smaller NPs can facilitate faster dissolution and showing higher level of toxicity.³⁰ The combined effect between the activity of the NPs and releasing ions may result in cell disruption.³¹

As shown in the results, CuO NPs have interesting antibacterial effects; however, the literature has reported a decrease of cell viability in cell lines exposed to metal NPs.³² As one of our limitations, it was probable that the cytotoxic effects of CuO NPs also evaluated. However, Prabhu et al. showed that in short-time period copper NPs at low concentrations (10 and 20 µM) did not any

significant effect on cell culture morphology and cell viability.³³ Moreover, the lack of minimum inhibitory concentrations (MICs) evaluation can be mentioned as final limitation.

Conclusion

In summary, CuO NPs as an alternative to conventional antibiotics that are currently used showed dose-dependent antibacterial activity against different uropathogenic bacteria, specificity towards pathogenic Gram-positive bacteria. This promising antibacterial activity of CuO NPs suggesting the development of NPs coatings on the different surface of biomedical materials for applications in different antimicrobial control systems.

Acknowledgments

This study was supported by Nanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran with grant No. 94-9387.

Conflict of Interests

The authors claim that there is no conflict of interest.

References

1. Sydnor ER, Perl TM. Hospital epidemiology and infection control in acute-care settings. *Clin Microbiol Rev.* 2011;24(1):141-73. doi:10.1128/CMR.00027-10
2. Khan HA, Ahmad A, Mehboob R. Nosocomial infections and their control strategies. *Asian Pac J Trop Biomed.* 2015;5(7):509-14. doi:10.1016/j.apjt.2015.05.001
3. Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. *Ther Adv Drug Saf.* 2014;5(6):229-41. doi:10.1177/2042098614554919
4. Salehi B, Mehrabian S, Ahmadi M. investigation of antibacterial effect of cadmium oxide nanoparticles on *Staphylococcus aureus* bacteria. *J Nanobiotechnology.* 2014;12(1):26. doi:10.1186/s12951-014-0026-8
5. Ebrahim-Saraie HS, Motamedifar M, Sarvari J, Hoseini Alfatemi SM. Emergence of SCCmec type I obtained from clinical samples in Shiraz teaching hospitals, South-West of Iran. *Jundishapur J Microbiol.* 2015;8(6):e16998. doi:10.5812/jjm.16998v2
6. Kaveh M, Bazargani A, Ramzi M, Sedigh Ebrahim-Saraie H, Heidari H. Colonization rate and risk factors of vancomycin-resistant enterococci among patients received hematopoietic stem cell transplantation in Shiraz, Southern Iran. *Int J Organ Transplant Med.* 2016;7(4):197-205.
7. Kazemian H, Heidari H, Ghanavati R, Mohebi R, Ghafourian S, Shavalipour A, et al. Characterization of antimicrobial resistance pattern and molecular analysis among extended spectrum β-lactamase-producing *Escherichia coli*. *Pharm Sci.* 2016;22(4):279-84. doi:10.15171/ps.2016.43

8. Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. *Perspect Medicin Chem.* 2014;6:25-64. doi:10.4137/pmc.s14459
9. Kazemian H, Ghafourian S, Heidari H, Amiri P, Yamchi JK, Shavalipour A, et al. Antibacterial, anti-swarming and anti-biofilm formation activities of *Chamaemelum nobile* against *Pseudomonas aeruginosa*. *Rev Soc Bras Med Trop.* 2015;48(4):432-6. doi:10.1590/0037-8682-0065-2015
10. Taylor E, Webster TJ. Reducing infections through nanotechnology and nanoparticles. *Int J Nanomedicine.* 2011;6:1463-73. doi:10.2147/ijn.s22021
11. Hajipour MJ, Fromm KM, Ashkarran AA, Jimenez de Aberasturi D, de Larramendi IR, Rojo T, et al. Antibacterial properties of nanoparticles. *Trends Biotechnol.* 2012;30(10):499-511. doi:10.1016/j.tibtech.2012.06.004
12. Hoseini-Alfatemi SM, Karimi A, Armin S, Fakharzadeh S, Fallah F, Kalanaky S. Antibacterial and antibiofilm activity of nanochelating based silver nanoparticles against several nosocomial pathogens. *Appl Organomet Chem.* 2018;32(5):e4327. doi:10.1002/aoc.4327
13. Heidari H, Hasanpour S, Ebrahim-Saraie HS, Motamedifar M. High Incidence of Virulence Factors Among Clinical *Enterococcus faecalis* Isolates in Southwestern Iran. *Infect Chemother.* 2017;49(1):51-6. doi:10.3947/ic.2017.49.1.51
14. Ebrahim-Saraie HS, Heidari H, Khashei R, Edalati F, Malekzadegan Y, Motamedifar M. Trends of antibiotic resistance in staphylococcus aureus isolates obtained from clinical specimens. *J Krishna Inst Med Sci Univ.* 2017;6(3):19-30.
15. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect.* 2012;18(3):268-81. doi:10.1111/j.1469-0691.2011.03570.x
16. Nanda A, Saravanan M. Biosynthesis of silver nanoparticles from *Staphylococcus aureus* and its antimicrobial activity against MRSA and MRSE. *Nanomedicine.* 2009;5(4):452-6. doi:10.1016/j.nano.2009.01.012
17. Najjar MS, Saldanha CL, Banday KA. Approach to urinary tract infections. *Indian J Nephrol.* 2009;19(4):129-39. doi:10.4103/0971-4065.59333
18. Chen M, Yu Q, Sun H. Novel strategies for the prevention and treatment of biofilm related infections. *Int J Mol Sci.* 2013;14(9):18488-501. doi:10.3390/ijms140918488
19. Agarwala M, Choudhury B, Yadav RN. Comparative study of antibiofilm activity of copper oxide and iron oxide nanoparticles against multidrug resistant biofilm forming uropathogens. *Indian J Microbiol.* 2014;54(3):365-8. doi:10.1007/s12088-014-0462-z
20. Khashan KS, Sulaiman GM, Abdulameer FA. Synthesis and antibacterial activity of copper nanoparticles suspension induced by laser ablation in liquid. *ARAB J SCI ENG.* 2016;41(1):301-10. doi:10.1007/s13369-015-1733-7
21. Usman M, El Zowalaty M, Shameli K, Zainuddin N, Salama M, Ibrahim NA. Synthesis, characterization, and antimicrobial properties of copper nanoparticles. *Int J Nanomedicine.* 2013;8(1):4467-79. doi:10.2147/ijn.s50837
22. Ruparelia JP, Chatterjee AK, Duttagupta SP, Mukherji S. Strain specificity in antimicrobial activity of silver and copper nanoparticles. *Acta Biomater.* 2008;4(3):707-16. doi:10.1016/j.actbio.2007.11.006
23. Kora AJ, Arunachalam J. Assessment of antibacterial activity of silver nanoparticles on *Pseudomonas aeruginosa* and its mechanism of action. *World J Microbiol Biotechnol.* 2011;27(5):1209-16. doi:10.1007/s11274-010-0569-2
24. Paredes D, Ortiz C, Torres R. Synthesis, characterization, and evaluation of antibacterial effect of Ag nanoparticles against *Escherichia coli* O157:H7 and methicillin-resistant *Staphylococcus aureus* (MRSA). *Int J Nanomedicine.* 2014;9(1):1717-29. doi:10.2147/ijn.s57156
25. Azam A, Ahmed AS, Oves M, Khan MS, Habib SS, Memic A. Antimicrobial activity of metal oxide nanoparticles against gram-positive and gram-negative bacteria: a comparative study. *Int J Nanomedicine.* 2012;7:6003-9. doi:10.2147/ijn.s35347
26. Ghasemian E, Naghoni A, Rahvar H, Kialha M, Tabaraie B. Evaluating the effect of copper nanoparticles in inhibiting *Pseudomonas aeruginosa* and *Listeria monocytogenes* biofilm formation. *Jundishapur J Microbiol.* 2015;8(5):e17430. doi:10.5812/jjm.17430
27. Amiri M, Etemadifar Z, Daneshkazemi A, Nateghi M. Antimicrobial effect of copper oxide nanoparticles on some oral bacteria and candida species. *J Dent Biomater.* 2017;4(1):347-52.
28. DeAlba-Montero I, Guajardo-Pacheco J, Morales-Sanchez E, Araujo-Martinez R, Loredano-Becerra GM, Martinez-Castanon GA, et al. Antimicrobial properties of copper nanoparticles and amino acid chelated copper nanoparticles produced by using a soya extract. *Bioinorg Chem Appl.* 2017;2017:1-6. doi:10.1155/2017/1064918
29. Vincent M, Duval RE, Hartemann P, Engels-Deutsch M. Contact killing and antimicrobial properties of copper. *J Appl Microbiol.* 2018;124(5):1032-46. doi:10.1111/jam.13681
30. Reidy B, Haase A, Luch A, Dawson KA, Lynch I. Mechanisms of silver nanoparticle release, transformation and toxicity: A critical review of current knowledge and recommendations for future studies and applications. *Materials.* 2013;6(6):2295-350. doi:10.3390/ma6062295

31. Franci G, Falanga A, Galdiero S, Palomba L, Rai M, Morelli G, et al. Silver nanoparticles as potential antibacterial agents. *Molecules*. 2015;20(5):8856-74. doi:10.3390/molecules20058856
32. Bahadar H, Maqbool F, Niaz K, Abdollahi M. Toxicity of Nanoparticles and an Overview of Current Experimental Models. *Iran Biomed J*. 2016;20(1):1-11.
33. Prabhu BM, Ali SF, Murdock RC, Hussain SM, Srivatsan M. Copper nanoparticles exert size and concentration dependent toxicity on somatosensory neurons of rat. *Nanotoxicology*. 2010;4(2):150-60. doi:10.3109/17435390903337693